Categories
Change Password!
Reset Password!
In early T2DM, 5:2 intermittent fasting meal replacement outperforms standard therapies in reducing BMI, abdominal fat, and body fat.
Evidence from a new study suggests that adopting a 5:2 intermittent fasting meal replacement (5:2 MR) regimen leads to better weight management, improved body composition, and greater abdominal fat reduction than standard pharmacological treatments like metformin and empagliflozin) in early type 2 diabetes mellitus (T2DM).
This single-center, randomized, active-controlled EARLY trial included 85 overweight and obese adults with early T2DM, assigned to:
The intervention lasted 16 weeks, with body composition measured via InBody analysis and abdominal fat distribution assessed via energy spectrum computed tomography scans. Correlations between body-mass index (BMI) reduction and fat-related outcomes were evaluated using Spearman’s coefficient. Intermittent fasting exhibited superior fat loss and metabolic benefits (Table 1).
In the 5:2 MR group, BMI reduction strongly correlated with improvements in abdominal fat markers, reinforcing its metabolic benefits:
The findings suggest that 5:2 intermittent fasting with meal replacement is a powerful non-pharmacological strategy for:
Clinical Nutrition
Effects of 5:2 intermittent fasting meal replacement on body composition and abdominal fat distribution in overweight and obese adults with early type 2 diabetes
Dongni Yu et al.
Comments (0)